CASE REPORT
Published on 10 Feb 2025
Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review
doi 10.3389/fonc.2025.1395129
- 801 views
- 1 citation
- Frontiers in Oncology
- Pharmacology of Anti-Cancer Drugs
- Research Topics
- Safety consideration in the development of anti-tumor monoclonal antibodies during drug development
Safety consideration in the development of anti-tumor monoclonal antibodies during drug development
6,292
Total downloads
19k
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 21 Aug 2024
Comparative analysis of adverse event risks in breast cancer patients receiving pembrolizumab combined with paclitaxel versus paclitaxel monotherapy: insights from the FAERS database
doi 10.3389/fphar.2024.1345671
- 1,568 views
- 1 citation
ORIGINAL RESEARCH
Published on 08 Aug 2024
In silico evaluation of the role of Fab glycosylation in cetuximab antibody dynamics
doi 10.3389/fimmu.2024.1429600
- 2,538 views
- 2 citations
ORIGINAL RESEARCH
Published on 23 Jul 2024
A two-stage maintenance trial of cetuximab-based treatment in RAS and BRAF wild-type unresectable metastatic colorectal cancer: a retrospective real-world study
doi 10.3389/fonc.2024.1425203
- 1,198 views
ORIGINAL RESEARCH
Published on 25 Jun 2024
A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)
doi 10.3389/fphar.2024.1405023
- 2,465 views
- 3 citations
REVIEW
Published on 30 Apr 2024
Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer
doi 10.3389/fonc.2024.1379738
- 4,071 views
- 10 citations
ORIGINAL RESEARCH
Published on 05 May 2023
Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab
doi 10.3389/fonc.2023.1164949
- 3,059 views
- 6 citations
Published in
Frontiers in Oncology
Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Pharmacology
- 4.4 impact factor
- 7.8 citescore